Repligen Corporation
Viés de alta
Atualizado

RGEN

132
Opening price: 178.47
SL: 172.01 (-3.62%)
TP: 197.86 (+10.86%)
R:R: 3

Fundamentals:
EPS % Chg (Last Qtr): 27%
3 Year EPS Growth Rate: 29%
EPS Est % Chg (Current Yr): 20%
Sales % Chg (Last Qtr): 24%
3-Year Sales Growth Rate: 39%
Annual Pre -Tax Margin: 24.9%

Story:
The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process.
Portion of the biotech industry without exposure to the full risks of the of drug approval process.
Strong double-digit growth.
COVID has a overall effect of increasing demand for Repligen products that helps make the vaccines and therapeutic drugs designed to combat the disease.
Earnings report at Nov 5.

Technicals
VCP near 52-week high + Breakout
Nota
Stopped out - 3.62% loss

Aviso legal

As informações e publicações não se destinam a ser, e não constituem, conselhos ou recomendações financeiras, de investimento, comerciais ou de outro tipo fornecidos ou endossados pela TradingView. Leia mais nos Termos de Uso.